{
  "issued_date": "2013-03-06", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON247079", 
  "doc_details": {
    "Type": "Drug Alert", 
    "Series No": "EL (13)A/09", 
    "Audience": "Healthcare professionals", 
    "Published": "6 March 2013", 
    "Format": "Electronic only", 
    "Size": "A4", 
    "Pages": "2", 
    "Price": "Free", 
    "ISBN/ISSN": "", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": " Class 4 Drug Alert (Caution in Use): Cytarabine Injection 100mg/ml (1g/10ml) - Hospira UK Limited - EL (13)A/09 (182Kb)", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/is-md/documents/websiteresources/con247096.pdf", 
      "filename": "downloads/78b8372c737f0a52599cd3b945daea2f3a2f0dca/con247096.pdf", 
      "original_filename": "con247096.pdf"
    }
  ], 
  "body": "## DRUG ALERT\n\nCLASS 4 MEDICINES DEFECT INFORMATION\n\nCaution in Use\n\n  \n\n\nDistribute to Hospital Pharmacy Level  \n  \n06 March 2013  |   |  EL (13)A/09  |   |  Our ref:\u00a0 MDR 03-03/13   | \n\n* * *\n\nDear Healthcare Professional,\n\nHospira UK Limited\n\nCytarabine Injection 100mg/ml (1g/10ml)\n\nPL 04515/0057\n\n  \n  \n  \nBatch number |   | Expiry date |   | Pack size |   | First distributed |   \nZ031966AA |   | March 2014 |   | 1 x 10 ml |   | 06 December 2012 | \n\nHospira UK Limited has identified the potential for crystallisation in the above batch of Cytarabine Injection 100mg/ml (1g/10ml). The crystals have been determined to be the active ingredient Cytarabine. Hospira UK Limited have identified the most probable cause for crystallisation is from particles of dried Cytarabine introduced during the filling process, which acted as a seed for crystal formation.\n\nThe company has informed the MHRA that no adverse events have been reported in connection with this crystallisation issue.\n\nHealthcare Professionals are asked to visually inspect vials for particulate matter prior to use. If crystals are found the product should not be used.\n\nTo obtain replacement stock please contact Hospira UK Limited Customer Services on custserv@hospira.com\n\nFor medical information enquiries please contact Hospira UK Limited Medical Information on +44 1926 834400, or e-mail [medinfouk@hospira.com](mailto:medinfouk@hospira.com)\n\nRecipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary care trusts are asked to forward this to relevant clinics and to general practitioners and community pharmacists for information.\n\nYours faithfully  \n  \nAdam Burgess  \nMHRA DMRC Manager\n\nMHRA Distribution (further recipients by cascade):  Regional Contacts for NHS Trusts and provider units  \nChief Pharmacists: England, Scotland, Wales, Northern Ireland  \nPrison health policy unit (DH)  \nChief pharmacists: \u00a0Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar  \nSpecial hospitals  \nHealthcare Commission for distribution to independent health care establishments  \nPrimary care trusts (England) \n\n### Download documents:  \n  \n  * [ASSET_TAG](#ASSET0)\n", 
  "raw_html": "<div class=\"inner\">          \r\n\t\t\t\t<a name=\"main\"></a>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"title\">\r\n\t\t\t\t\t<h2>DRUG ALERT</h2>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element14)-->\r\n\t\t\t\t\t<p>CLASS 4 MEDICINES DEFECT INFORMATION</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element14)-->\r\n\t\t\t\t</div>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"drugalertdetails\">\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<p>Caution in Use</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<br>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element16)-->\r\n\t\t\t\t\t<p>Distribute to Hospital Pharmacy Level</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element16)-->\r\n\t\t\t\r\n\t\t\t\t\t<table id=\"dateref\">\r\n\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t<td align=\"left\">\r\n\t\t\t\t\t\t\t\r\n\r\n\t\t\t\t\t\t\t06 March 2013\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td>\r\n\t\t\t\t\t\t\tEL (13)A/09\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td align=\"right\">\r\n\t\t\t\t\t\t\t\tOur ref:&#160;\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t\t MDR 03-03/13 \r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t</table>\r\n\t\t\t\t</div>\r\n\t\t\t\t<hr>\t\t\t\t\r\n          \t\t<!--SS_BEGIN_ELEMENT(region1_element12)-->\r\n          \t\t<!--SS_END_ELEMENT(region1_element12)--> \r\n          \t\t\r\n          \t\t \r\n          \t\t\r\n          \t\t<p>Dear Healthcare Professional,</p>\r\n\r\n\t\t\t\t<div class=\"druginfo\">\r\n\t\t\t\t\t<div class=\"left\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Hospira UK Limited</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\t\t\t\t\r\n          \t\t          \t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Cytarabine Injection 100mg/ml (1g/10ml)</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\r\n\t\t\t\t\t\r\n\t\t\t\t\t<div class=\"right\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<span>PL 04515/0057</span>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\t\r\n\t\t\t\t</div>\t\t\t\t\r\n          \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment8,navigation_controls)-->\r\n\t\t\t\t<!-- only show the publication navigation controls if there is more than one page to the publication -->\r\n\t\t\t\r\n\t\t\t\t<!-- SS_END_SNIPPET(fragment8,navigation_controls)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t<!-- <br>SS_DATAFILE: CON247079 -->\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<p><br>\n</p><table border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tr>\n<td valign=\"top\" width=\"141\"><span>Batch number</span></td>\n<td valign=\"top\" width=\"148\"><span>Expiry date</span></td>\n<td valign=\"top\" width=\"148\"><span>Pack size</span></td>\n<td valign=\"top\" width=\"157\"><span>First distributed</span></td>\n</tr>\n\n<tr>\n<td valign=\"top\" width=\"141\">Z031966AA</td>\n<td valign=\"top\" width=\"148\">March 2014</td>\n<td valign=\"top\" width=\"148\">1 x 10 ml</td>\n<td valign=\"top\" width=\"157\">06 December 2012</td>\n</tr>\n</table>\n\n<p>Hospira UK Limited has identified the potential for crystallisation in the above batch of Cytarabine Injection 100mg/ml (1g/10ml). The crystals have been determined to be the active ingredient Cytarabine. Hospira UK Limited have identified the most probable cause for crystallisation is from particles of dried Cytarabine introduced during the filling process, which acted as a seed for crystal formation.</p>\n\n<p>The company has informed the MHRA that no adverse events have been reported in connection with this crystallisation issue.</p>\n\n<p>Healthcare Professionals are asked to visually inspect vials for particulate matter prior to use. If crystals are found the product should not be used.</p>\n\n<p>To obtain replacement stock please contact Hospira UK Limited Customer Services on custserv@hospira.com</p>\n\n<p>For medical information enquiries please contact Hospira UK Limited Medical Information on +44 1926 834400, or e-mail <a href=\"mailto:medinfouk@hospira.com\">medinfouk@hospira.com</a></p>\n\n<p>Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary care trusts are asked to forward this to relevant clinics and to general practitioners and community pharmacists for information.</p>\n\n<p>Yours faithfully<br>\n<br>\nAdam Burgess<br>\nMHRA DMRC Manager</p>\r\n\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t\r\n        \t\tMHRA Distribution (further recipients by cascade):\r\n        \t\t\r\n        \t\t <!--SS_BEGIN_ELEMENT(region1_element18)-->\r\n        \t\tRegional Contacts for NHS Trusts and provider units<br>\nChief Pharmacists: England, Scotland, Wales, Northern Ireland<br>\nPrison health policy unit (DH)<br>\nChief pharmacists: &#160;Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar<br>\nSpecial hospitals<br>\nHealthcare Commission for distribution to independent health care establishments<br>\nPrimary care trusts (England)\r\n        \t\t<!--SS_END_ELEMENT(region1_element18)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element3,static_pdf_list)-->\r\n        \t\t<!-- the xmlListTag variable is used by the searchDocsByContentIdList include to map the name of the XML node which contains the content id -->\r\n<!--perform the search -->\r\n\t\r\n\t<!-- <br>root: Content/AssociatedContent -->\r\n\t<!-- <br>ssFragmentInstanceId: region1_element3\t -->\r\n\t<!-- <br>SS_DATAFILE: CON247079 -->\r\n\t<!-- <br>xmlListTag: ContentId\t -->\r\n\t<!-- <br>XPATH: CON247079/Content/AssociatedContent/ContentId\t -->\r\n\r\n\t<!-- xmlListTag variable should be the name of the xml node which contains a contentid.  there should be a lis of these in the XML -->\r\n\t<!-- <br>strNumRecords: 1 -->\r\n\t<!-- <br>nNumRecords: 1 -->\r\n\r\n\t\t\t<!-- using the content ID above, get the docment from conetent server-->\r\n\r\n\t\t\t\r\n\r\n\t\t<!--  dDocName <matches>`CON247096` -->\r\n\t\t\r\n<div id=\"downloadArea\">\r\n\t<h3>Download documents:</h3>\r\n\t<ul>\r\n\t\t<!-- the SearchResults will have been initialised by the call to searchDocsByContentIdList above-->\r\n\t\t\t\r\n\t\t\t\t<li>\r\n\r\n\t\t\t\t\t\t<a href=\"#ASSET0\">ASSET_TAG</a>\r\n\t\t\t\t</li>\r\n\t</ul>\r\n\t<div class=\"clearing\"><!--  --></div>\r\n\t<!--<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/readstep2.html\">Download Acrobat Reader for free</a></p>\r\n\t<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/access_onlinetools.html\">Adobe text conversion tools</a></p>-->\r\n</div>\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element3,static_pdf_list)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_CLOSEREGIONMARKER(region1)-->\r\n        \t\t\r\n        \t\t<!-- SS_END_CLOSEREGIONMARKER(region1)-->\r\n\t\t\t</div>\r\n\t\t", 
  "title": "Class 4 Drug Alert (Caution in Use): Cytarabine Injection 100mg/ml (1g/10ml) - Hospira UK Limited - EL (13)A/09", 
  "alert_type": [
    "drugs"
  ], 
  "medical_specialism": []
}